{"id":979793,"date":"2026-07-08T12:36:49","date_gmt":"2026-07-08T16:36:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/"},"modified":"2026-07-08T12:36:49","modified_gmt":"2026-07-08T16:36:49","slug":"crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/","title":{"rendered":"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX"},"content":{"rendered":"<p>        <!--.bwalignl { text-align: left }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignl\">Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX<\/p>\n<p class=\"bwalignl\">NEW YORK &amp; NEW ORLEANS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ksfcounsel.com%2F&amp;esheet=54567265&amp;newsitemid=20260708039070&amp;lan=en-US&amp;anchor=Kahn+Swick+%26+Foti&amp;index=514&amp;md5=dd76154236e9a044471cb4c477219f66\">Kahn Swick &amp; Foti<\/a>, LLC (\u201cKSF\u201d) are investigating the proposed sale of <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-crnx%2F&amp;esheet=54567265&amp;newsitemid=20260708039070&amp;lan=en-US&amp;anchor=Crinetics+Pharmaceuticals&amp;index=515&amp;md5=6f53064d5a32838a4b231d61ac07023b\">Crinetics Pharmaceuticals<\/a>, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.<\/p>\n<p class=\"bwalignl\">If you believe that this transaction undervalues the Company and\/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (<a rel=\"nofollow\" href=\"mailto:lewis.kahn@ksfcounsel.com\">lewis.kahn@ksfcounsel.com<\/a>) toll free at any time at 855-768-1857, or visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-crnx%2F&amp;esheet=54567265&amp;newsitemid=20260708039070&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.ksfcounsel.com%2Fcases%2Fnasdaqgs-crnx%2F&amp;index=516&amp;md5=a671826305e8f52db9c9dde274b2060b\">https:\/\/www.ksfcounsel.com\/cases\/nasdaqgs-crnx\/<\/a> to learn more.<\/p>\n<p class=\"bwalignl\">To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ksfcounsel.com&amp;esheet=54567265&amp;newsitemid=20260708039070&amp;lan=en-US&amp;anchor=www.ksfcounsel.com&amp;index=517&amp;md5=f24deefa950b592b7e1d6f763fb70a9e\">www.ksfcounsel.com<\/a>.<\/p>\n<p class=\"bwalignl\">CONNECT WITH US: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2Fprofile.php%3Fid%3D61575733915628&amp;esheet=54567265&amp;newsitemid=20260708039070&amp;lan=en-US&amp;anchor=Facebook&amp;index=518&amp;md5=ff34c6882f22f929b796eee1df126cd6\">Facebook<\/a> || <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fkahn_swick_and_foti%2F&amp;esheet=54567265&amp;newsitemid=20260708039070&amp;lan=en-US&amp;anchor=Instagram&amp;index=519&amp;md5=920f8bbb8c33d4e97337bad614fbcc4d\">Instagram<\/a> || <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2F%40kahnswickandfoti&amp;esheet=54567265&amp;newsitemid=20260708039070&amp;lan=en-US&amp;anchor=YouTube&amp;index=520&amp;md5=eb413aa21e6bf1d139744e1299559408\">YouTube<\/a> || <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.tiktok.com%2F%40kahn.swick.foti&amp;esheet=54567265&amp;newsitemid=20260708039070&amp;lan=en-US&amp;anchor=TikTok&amp;index=521&amp;md5=efda61db75d0578f6c9521547dc994ca\">TikTok<\/a> || <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fksfcounsel&amp;esheet=54567265&amp;newsitemid=20260708039070&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=522&amp;md5=cd65e23bae577d8c31631f251fbd90e1\">LinkedIn<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260708039070\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260708039070\/en\/<\/a><\/span><\/p>\n<p class=\"bwalignl\">Kahn Swick &amp; Foti, LLC<br \/>Lewis S. Kahn, Managing Partner<br \/><a rel=\"nofollow\" href=\"mailto:lewis.kahn@ksfcounsel.com\">lewis.kahn@ksfcounsel.com<\/a><br \/>855-768-1857<br \/>1100 Poydras St., Suite 960<br \/>New Orleans, LA 70163<\/p>\n<p><b>KEYWORDS:<\/b> Louisiana New York United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Class Action Lawsuit Professional Services Legal<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260708039070\/en\/2664609\/3\/2025-PR-MA.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX NEW YORK &amp; NEW ORLEANS&#8211;(BUSINESS WIRE)&#8211;Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-979793","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX NEW YORK &amp; NEW ORLEANS&#8211;(BUSINESS WIRE)&#8211;Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction &hellip; Continue reading &quot;Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T16:36:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX\",\"datePublished\":\"2026-07-08T16:36:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/\"},\"wordCount\":280,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/\",\"name\":\"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-07-08T16:36:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/","og_locale":"en_US","og_type":"article","og_title":"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX - Market Newsdesk","og_description":"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX NEW YORK &amp; NEW ORLEANS&#8211;(BUSINESS WIRE)&#8211;Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (\u201cKSF\u201d) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed transaction, shareholders of Crinetics will receive $85.00 in cash for each share of Crinetics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction &hellip; Continue reading \"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-08T16:36:49+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX","datePublished":"2026-07-08T16:36:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/"},"wordCount":280,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/","name":"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-07-08T16:36:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260708039070r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crinetics-pharmaceuticals-investor-alert-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-crinetics-pharmaceuticals-inc-crnx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Crinetics Pharmaceuticals Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. &#8211; CRNX"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/979793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=979793"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/979793\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=979793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=979793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=979793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}